Genprex (GNPX) Cash from Operations (2016 - 2026)
Genprex (GNPX) posted quarterly Cash from Operations of 3138457.0 for Q1 2026, up 24.58% year-over-year from 2519186.98 in Q1 2025, and up 23.42% quarter-over-quarter from 4098271.0 in Q4 2025.
Genprex (GNPX) Cash from Operations (2016 - 2026) Analysis & Trends
Genprex's Cash from Operations history runs 11 years deep, the most recent figure standing at 3138457.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 24.58% year-over-year to 3138457.0; the TTM figure through Mar 2026 stood at 14288242.0 (up 14.88% YoY), while the FY2025 annual figure was 15311209.0, up 14.57% from the prior year.
- Cash from Operations for Q1 2026 stood at 3138457.0, up from 4098271.0 in the prior quarter.
- The five-year high for Cash from Operations was 2185925.0 in Q3 2024, with the low at 8107101.0 in Q2 2023.
- The 5-year median for Cash from Operations is 4480468.0 (2022), against an average of 4631313.71.
- The sharpest annual moves came in 2023 and 2024: Cash from Operations tumbled 80.94% in 2023, then jumped 53.84% in 2024.
- Genprex's Cash from Operations stood at 4546658.0 in 2022, then retreated by 9.18% to 4963863.0 in 2023, then advanced by 22.05% to 3869430.0 in 2024, then fell by 5.91% to 4098271.0 in 2025, then gained by 23.42% to 3138457.0 in 2026.
- Business Quant data shows GNPX's Cash from Operations at 3138457.0 in Q1 2026, 4098271.0 in Q4 2025, and 3187278.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Genprex | 1.88 Mn | -13.28 Mn | - | -5.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.14 Mn |
| Mar 31, 2026 | -3.14 Mn |
| Dec 31, 2025 | -4.10 Mn |
| Dec 31, 2025 | -4.10 Mn |
| Sep 30, 2025 | -3.19 Mn |
| Sep 30, 2025 | -3.19 Mn |
| Jun 30, 2025 | -3.86 Mn |
| Jun 30, 2025 | -3.86 Mn |
| Mar 31, 2025 | -4.16 Mn |
| Mar 31, 2025 | -4.16 Mn |
| Dec 31, 2024 | -3.87 Mn |
| Dec 31, 2024 | -3.87 Mn |
| Sep 30, 2024 | -2.19 Mn |
| Sep 30, 2024 | -2.19 Mn |
| Jun 30, 2024 | -6.57 Mn |
| Jun 30, 2024 | -6.57 Mn |
| Mar 31, 2024 | -5.30 Mn |
| Mar 31, 2024 | -5.30 Mn |
| Dec 31, 2023 | -4.96 Mn |
| Dec 31, 2023 | -4.96 Mn |